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Key findings
• The prevalence of hepatitis 
A antibody, which is indicative 
of immunity to hepatitis A 
virus, increased among U.S. 
born persons aged 6-19, but 
decreased among persons aged 
40 years and over.
• Hepatitis B virus (HBV) 
infection among persons aged 
6-19 has decreased in recent 
years. By 2003-2006, over 
90% of children had received 
at least one dose of the recom­
mended three-dose series of 
hepatitis B vaccine.
• Prevalence of infection 
with hepatitis C virus (HCV) 
decreased among those at 
highest risk of infection 
including males and Mexican- 
American and non-Hispanic 
black populations. Despite this 
decrease, the prevalence of 
infection remains higher in 
the non-Hispanic black popu­
lation. The peak prevalence 
of HCV infection has shifted 
over time from persons aged 
30-39 years (3.9%) to those 
aged 40-49 years (4.3%).
Viral hepatitis is a disease of major public health significance in the United 
States with most infection caused by three viruses, hepatitis A virus (HAV), 
hepatitis B virus (HBV), and hepatitis C virus (HCV) (1). Although unre­
lated, they share a similar symptomatology (2). HBV and HCV can produce 
chronic infection that is associated with chronic liver disease and liver cancer. 
Because 70-85% of those acutely infected with HCV become chronically 
infected, HCV is the most common chronic bloodborne infection in the 
United States (3).
The vaccine for HAV has been recommended for travelers since 1995; 
children and others at risk since 2006 (4). The vaccine for HBV has been 
recommended for infants, older children and adolescents not previously vac­
cinated since 1991, and adults at risk since the early 1980s (5,6) . No vaccine 
currently exists for HCV. Effective antiviral treatments are available for HBV 
infection to halt progressive liver damage (7) and for hepatitis C to achieve 
“sustained virologic response” (i.e., virologic cure).
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Has there been a change in the prevalence of HAV antibody 
among the U.S. born population?
Figure 1. HAV antibody prevalence among U.S. born persons aged 6 -19  years: NHANES 
1988-1994, 1999-2002, 2003-2006, and 2007-2008
Survey years
1 p<0.05 fo r a test o f an increasing linear trend with tim e fo r the  tota l population and all race/e thn ic groups.
2 p<0.05 when com paring the  M exican-Am erican population w ith the  non-H ispanic w h ite  and the  non-H ispanic black 
populations fo r all tim e periods.
NOTES: HAV is hepatitis A virus. All estim ates are  age adjusted. All includes race/ethnic groups not reported separately.
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The prevalence of HAV antibody among persons aged 6-19 years increased steadily over the four 
time periods from 8.0% in 1988-1994 to 35.3% in 2007-2008 (Figure 1). Among persons aged 
20-29 years, the prevalence of HAV antibody increased overall from 8.9% in 1988-1994 to 17.1 
in 2003-2006 (Figure 2, HAV antibody was not measured among persons aged 19 years and over 
in 2007-2008). There was no change over time in HAV antibody among persons aged 30-39 
years. Among adults aged 40 years and over, there was a decline in the HAV antibody prevalence 
from 1988-1994 to 2003-2006.
Are there differences in HAV antibody prevalence by race/ethnicity and 
were they consistent over time?
For all time periods, the Mexican-American population had a significantly higher prevalence of 
HAV antibody compared with the non-Hispanic white and non-Hispanic black populations among 
both children aged 6-19 years (Figure 1) and adults aged 20 years and over (Figure 2).
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1 Estimates are age adjusted.
2 p<0.05 for test o f linear trend decreasing with time among the total, non-H ispanic white, non-H ispanic black, and Mexican- 
Am erican populations; and age groups 40 -49 , 50 -59 , and 60 years and over.
3 p<0.05 for test o f linear trend increasing w ith tim e among those aged 20-29  years.
4 p <0.05 when comparing the non-H ispanic white population with the non-H ispanic black population, all time periods.
5 p <0.05 when comparing the non-H ispanic white population with the M exican-Am erican population, all time periods.
6 p <0.05 when comparing the non-H ispanic black population with the M exican-Am erican population, all time periods.
NOTES: HAV is hepatitis A  virus. A ll includes race/e thn ic groups not reported separately .
Has the prevalence of HBV infection changed over time?
The overall prevalence of HBV infection among persons of all ages decreased from 1988-1994 
to 2007-2008 (Figure 3). The decrease in the prevalence of HBV infection from 1988-1994 to 
2007-2008 was significant for all age groups except for persons aged 40-59 years.
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Figure 3. HBV infection prevalence, by age group and survey cycle: NHANES 1988-1994, 1999-2002, 2003-2006, 
and 2007-2008
Survey years
1 p<0.05 for test for linear decreasing trend with time for age groups 6 -1 9 , 20-39 , 60 years and over, and all ages combined.
2 estim ates are  age adjusted.
r estim ate m ay be unstable because the relative standard error is g reater than 30%. 
p estim ate m ay be unstable because it is based on less than 10 positive persons.
NOTE: HBV is hepatitis B virus.
Did HBV infection vary by race/ethnicity, sex or place of birth, and how did 
prevalence change over time in these population subgroups?



















1 p<0.05 for test o f linear decreasing trend w ith tim e among all groups.
2 p<0.05 when com paring the non-H ispanic black population w ith both the non-H ispanic white and M exican-Am erican populations, all tim e periods.
3 p<0.05 when com paring the non-H ispanic white  population w ith the M exican-Am erican population, 1988-1994.
4 p<0.05 when com paring U.S. born persons w ith foreign born persons, all time periods.
5 p<0.05 when com paring males with fem ales, 1988-1994 , 1999-2002 , and 2003-2006.
NOTES: HBV is hepatitis B virus. A ll estim ates are age adjusted. A ll includes the race/e thn ic groups not reported separately.
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For all four time periods, the non-Hispanic black population had a higher prevalence of HBV in­
fection compared with the non-Hispanic white and Mexican-American populations. Persons born 
outside the United States had a higher prevalence of infection compared with those that were U.S. 
born (Figure 4). For the three time periods from 1988-2006, males also had higher prevalence of 
infection than females. HBV infection prevalence decreased from 1988-1994 to 2007-2008 for 
all racial/ethnic and demographic groups.
What percentage of the population aged 6-19 years reported vaccination 
with the HBV vaccine?
HBV vaccination (at least one dose) was reported for 73% of the population in 1999-2002. This 
increased to 90% and 91% in 2003-2006 and 2007-2008, respectively (data not shown).
Did HCV infection vary by race/ethnicity or sex, and how did prevalence 
change over time in these population subgroups?
The overall prevalence of HCV infection decreased from 1988-1994 to 2007-2008 (Figure 5). 
The non-Hispanic black population had significantly greater prevalence of HCV infection com­
pared with both the non-Hispanic white and Mexican-American populations across all survey

















1 p<0.05 for test o f decreasing linear trend with time from  1988-1994 through 2007-2008 am ong the total, male, and M exican-Am erican populations.
2 p<0.05 for test o f decreasing linear trend with time from  1988-1994 through 2003-2006  among the male, non-H ispanic black , and Mexican-Am erican populations.
3 p<0.05 when com paring males w ith fem ales, NHANES 1988-1994, NHANES 1999-2002, and NHANES 2003-2006.
4 p <0.05 when com paring the non-H ispanic white  population with the non-H ispanic black population, all survey cycles.
5 p<0.05 when com paring the non-H ispanic white  population with the M exican-Am erican population, 1988-1994  only.
6 p <0.05 when com paring the non-H ispanic black population with the M exican-Am erican population, all survey cycles. 
r estim ate m ay be unstable because the relative standard error is g reater than 30%.
NOTES: HCV is hepatitis C virus. A ll estim ates are  age adjusted. A ll includes race/e thn ic groups not reported separately.
cycles from 1988-2008. Among three subgroups, non-Hispanic black and Mexican-American 
persons and males, decreases in prevalence of HCV infection were observed from 1988-1994 
to 2003-2006. Among Mexican-American persons and males decreases were observed from 
1988-1994 to 2007-2008. In contrast, there was no change over time in prevalence among non- 
Hispanic white persons or among females.
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Did the prevalence of HCV infection by age group change over time?
For 1988-1994, persons aged 30-39 years had the highest prevalence of HCV infection (3.9%) 
(Figure 6) . By 1999-2002, the peak of infection had shifted to persons aged 40-49 years (4.3%). 
Peak infection remained among persons aged 40-49 years in 2003-2006 and 2007-2008.
Figure 6. HCV infection prevalence, by age and time periods: NHANES
Age
r estim ate m ay be unstable because the re la tive  standard error is g reater than 30%. 
p estim ate m ay be unstable because it is based on less than 10 positive persons.
NOTE: HCV is hepatitis C virus.
Summary
There was a significant increase in the prevalence of HAV antibody among U.S. born persons 
aged 6-19 years from 1988-1994 to 2007-2008 most likely reflecting increasing HAV immuniza­
tion of children and others. Among U.S. born adults (aged 40 years and over), HAV antibody 
prevalence decreased from 1988-1994 and 2003-2006. This may reflect lower rates of infection 
due to reduced exposure to the virus, resulting from higher rates of immunization among the 
younger age groups. Surveillance data also have recently demonstrated a decrease in incidence 
over the past 50 years to historic lows with the release of the HAV vaccine and changes in vac­
cination policy (4,8).
The significantly higher prevalence of HAV antibody among U.S. born Mexican-American 
children and adults may reflect not only higher rates of vaccination within this subgroup, but also 
continued greater exposure to natural infection from travel to or visitors from Mexico where the 
disease is endemic.
There was a significant decrease from 1988-1994 to 2007-2008 for the total population and 
for most age groups (6-19, 20-39, and 60 years and over) including the youngest age groups 
that were targeted for vaccination. Disparities continued with significantly higher HBV infec­
tion prevalence among non-Hispanic black persons, males, and foreign born persons for most 
time periods. Reported vaccination coverage among persons aged 6-19 years was over 70% by 
1999-2002 and increased to over 90% by 2003-2006.
Overall prevalence of HCV decreased from 1988-1994 to 2003-2006, but remained constant 
from 2003-2006 to 2007-2008. The decreases in HCV prevalence were observed among the 
subgroups at highest risk, which suggest a positive impact of prevention efforts (9) . Despite these 
apparent gains, rates remained high among non-Hispanic black persons compared with other
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race/ethnicity populations. The peak in age-specific prevalence shifted from aged 30-39 years in 
1988-1994 to aged 40-49 years by 1999-2002 and continued through 2007-2008. This shift in 
peak age group suggests younger cohorts in the later time periods are not being infected at the 
same rate as those in earlier time periods.
Limitations
National Health and Nutrition Examination Surveys (NHANES) do not include groups that may 
be considered at higher risk for hepatitis infection (i.e., those institutionalized, incarcerated, those 
in nonhospital based long-term care facilities, injection drug using homeless populations, etc.). 
Therefore, these data provide conservative estimates of disease prevalence.
Definitions
Prevalence of HAV antibody: Presence of HAV antibody reflects immunity due to vaccination or 
due to natural infection transmitted by close personal contact or ingestion of fecal contaminated 
food or drink. All analyses for HAV are restricted to those U.S. born because prevalence of HAV 
antibody is much higher among those not born in the U.S., possibly reflecting infection early in 
life prior to immigration.
Prevalence of HBV infection: Presence of HBV core antibody, a measure of lifetime infection 
transmitted through sexual contact, sharing contaminated needles, or from an infected mother 
to her newborn. HBV core antibody alone does not distinguish between history of infection and 
chronic active infection.
Prevalence of HCV infection: Presence of antibody to HCV, a measure of lifetime infection 
transmitted by contact with the blood of an infected person primarily through sharing contami­
nated needles.
Data source and methods
NHANES data were used for these analyses. NHANES is a cross-sectional survey designed to 
monitor the health and nutritional status of the civilian, noninstitutionalized U.S. population (10). 
The survey consists of interviews conducted in participant’s homes, standardized physical exami­
nations conducted in specially outfitted mobile examination centers, and laboratory tests utilizing 
blood provided by participants during the physical examination.
The NHANES sample design is a complex, multistage design that includes oversampling in 
order to obtain reliable estimates of health and nutritional measures for population subgroups. In 
NHANES III conducted from 1988 to 1994, children under age 5 years, persons aged 60 years 
and over, Mexican-American persons and non-Hispanic black persons were oversampled. In 
1999-2006, non-Hispanic black persons, Mexican-American persons, persons with low-income, 
persons aged 12-19 years, and persons aged 60 years and over were oversampled. In 2007-2008, 
adolescents were no longer oversampled. In 1999, NHANES became a continuous survey, fielded 
on an ongoing basis. Public use data files are released in 2-year cycles.
Sample weights, which account for the differential probabilities of selection, nonresponse and 
noncoverage, are incorporated into the estimation process. Standard errors of the estimates were 
calculated and tests of significance were conducted incorporating the sample weights and sample 
design (11). Prevalence estimates were age adjusted by the direct method to the projected 2000 
U.S. Census population for comparisons across population subgroups and between surveys (12).
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Tests for linear trends with time were examined using orthogonal contrast matrices (13). All data 
analyses were performed using SAS System for Windows (release 9.2; SAS Institute Inc, Cary 
N.C.) and SUDAAN (release 10.0; Research Triangle Institute, Research Triangle Park, N.C.).
Serum samples for persons aged 6 years and over (aged 6-19 years only for HAV testing in 
NHANES 2007-2008) were sent to the Division of Viral Hepatitis, National Center for HIV/ 
AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention for 
HAV, HBV, and HCV antibody testing.
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